



RESOURCE AND PATIENT MANAGEMENT SYSTEM

# **IHS Clinical Reporting System (BGP)**

## **Executive Order Quality Transparency Measures Report Performance Measure List and Definitions**

Version 9.0  
August 2009

Office of Information Technology (OIT)  
Division of Information Resource Management  
Albuquerque, New Mexico

## REVISION HISTORY

<b>Date</b>	<b>Revision</b>	<b>Description</b>	<b>Author</b>
05/27/09	1	Distribution to GPRA Coordinators and CRS listserv.	S. Klepacki
07/15/09	2	Adult Immunizations: Pneumovax: Removed the diabetes definition since the Active Diabetic denominator is not included in this topic in this report.	S. Klepacki

## TABLE OF CONTENTS

<b>1.0 Introduction</b> .....	<b>1</b>
1.1    CRS Denominator Definitions .....	1
1.1.1    For All Denominators .....	1
1.1.2    Active Clinical Population for National GPRA & PART Reporting.....	1
1.1.3    Active Clinical Population for Local Reports.....	2
1.1.4    User Population for National GPRA & PART Reporting .....	2
1.1.5    User Population for Local Reports.....	2
1.1.6    Active Clinical CHS Population for National GPRA & PART Reporting (CHS-only sites).....	3
1.1.7    Active Clinical CHS Population for Local Reports (CHS-only sites).....	3
<b>2.0 CRS EO Quality Transparency Measures Report Performance Measure Topics and Definitions</b> .....	<b>4</b>
2.1.1    Diabetes: Poor Glycemic Control .....	4
2.1.2    Diabetes: Blood Pressure Control.....	5
2.1.3    Diabetes: LDL Control.....	7
2.1.4    Adult Immunizations: Influenza .....	8
2.1.5    Adult Immunizations: Pneumovax.....	9
2.1.6    Use of Appropriate Medications for People with Asthma.....	10
2.1.7    Community-Acquired Pneumonia (CAP) Assessment of Oxygen Saturation (Changed from Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia).....	13
2.1.8    Persistence of Beta-Blocker Treatment After a Heart Attack.....	15
2.1.9    Controlling High Blood Pressure.....	18
2.1.10    Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge.....	20
2.1.11    Cholesterol Management for Patients with Cardiovascular Conditions .....	22
<b>3.0 Contact Information</b> .....	<b>24</b>

## 1.0 Introduction

The Executive Order (EO) Quality Transparency Measures Report contains performance measures that are in support of Executive Order 13410 for quality transparency reporting by Federal healthcare agencies. Federal facilities are required to run this report. All Federal sites will report their data annually and the information will be available on the new IHS Quality of Care web site.

Users have the option of running the report using the same hard-coded report parameters as the National GPRA & PART Report or selecting their own report parameters.

## 1.1 CRS Denominator Definitions

### 1.1.1 For All Denominators

- All patients with name “DEMO,PATIENT” will be excluded automatically for all denominators.
- For all measures except as noted, patient age is calculated as of the beginning of the Report Period.

### 1.1.2 Active Clinical Population for National GPRA & PART Reporting

- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the *Clinical Reporting System (CRS) for FY2009 Clinical Measures User Manual* for listing of these clinics.
- Must be alive on the last day of the Report Period.
- Must be American Indian/Alaska Native (AI/AN) - defined as Beneficiary 01.
- Must reside in a community specified in the site’s GPRA community taxonomy, defined as all communities of residence in the defined CHS catchment area.

### 1.1.3 Active Clinical Population for Local Reports

- Must have two visits to medical clinics in the past three years. Chart reviews and telephone calls from these clinics do not count; the visits must be face-to-face. At least one visit must be to a core medical clinic. Refer to the *Clinical Reporting System (CRS) for FY2009 Clinical Measures User Manual* for listing of these clinics.
- Must be alive on the last day of the Report Period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

### 1.1.4 User Population for National GPRA & PART Reporting

- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report Period.
- Must be American Indian/Alaska Native (AI/AN) - defined as Beneficiary 01.
- Must reside in a community specified in the site's GPRA community taxonomy, defined as all communities of residence in the defined CHS catchment area.

### 1.1.5 User Population for Local Reports

- Must have been seen at least once in the three years prior to the end of the time period, regardless of the clinic type, and the visit must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report Period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

### **1.1.6 Active Clinical CHS Population for National GPRA & PART Reporting (CHS-only sites)**

- Must have two CHS visits in the three years prior to the end of the Report Period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report period.
- Must be American Indian/Alaska Native (AI/AN) - defined as Beneficiary 01. This data item is entered and updated during the Patient Registration process.
- Must reside in a community included in the site's "official" GPRA community taxonomy, defined as all communities of residence in the CHS catchment area specified in the community taxonomy specified by the user.

### **1.1.7 Active Clinical CHS Population for Local Reports (CHS-only sites)**

- Must have two CHS visits in the three years prior to the end of the Report Period, and the visits must be either ambulatory (including day surgery or observation) or a hospitalization; the rest of the service categories are excluded.
- Must be alive on the last day of the Report period.
- User defines population type: AI/AN patients only, non AI/AN, or both.
- User defines general population: single community, group of multiple communities (community taxonomy), user-defined list of patients (patient panel), or all patients regardless of community of residence.

## 2.0 CRS EO Quality Transparency Measures Report Performance Measure Topics and Definitions

The following sections define the performance measure topics and their definitions that are included in the CRS 2009 Version 9.0 EO Quality Transparency Measures Report.

**Note:** “QoC” indicates the numerators and denominators of transparency measures that are or will be reported on the IHS Quality of Care Web Site (<http://www.ihs.gov/NonMedicalPrograms/quality/>).

### 2.1.1 Diabetes: Poor Glycemic Control

Changes from Version 8.0 Patch 3 noted below.

#### Owner/Contact

Diabetes Program/Dr. Marie Russell

#### Denominator

**QoC:** Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report period, AND at least 2 visits during the Report period, AND 2 DM-related visits ever.

#### Numerator

**QoC:** Patients with A1c greater than (>) 9.0 or patients with no test or a test with no value.

#### Definition

- 1) **Diabetes:** First Purpose of Visit 250.00-250.93 recorded in the V POV file prior to the Report Period.
- 2) **A1c:** Searches for most recent A1c test during the Report Period. *If more than one A1c test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.* If it has a result of > 9.0 or has no result, or if the patient does not have an A1c test during the Report Period, the patient will be included in the numerator as having poor A1c control. A1c defined as: CPT 83036, 83037, 3044F, 3045F, 3046F, or 3047F; LOINC taxonomy; or site-populated taxonomy DM AUDIT HGB A1C TAX. A1c tests documented with CPT 3046F indicate a result > 9.0 and will be included in the Poor Control numerator. A1c tests documented with CPT 83036 or 83037 indicate tests with no result and will be included in the Poor Control numerator. A1c tests documented with CPT 3044F, 3045F or 3047F indicate a result of =< 9.0 and will NOT be included in the numerator.

#### Patient List

List of diabetic patients with most recent A1c value, if any.

## 2.1.2 Diabetes: Blood Pressure Control

### No changes from Version 8.0 Patch 3.

#### Owner/Contact

Diabetes Program/Dr. Marie Russell

#### Denominator

**QoC:** Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report period, AND at least 2 visits during the Report period, AND 2 DM-related visits ever.

#### Numerator

**QoC:** Patients with BP level of <140/90 during the Report Period, i.e., the mean systolic value is less than 140 AND the mean diastolic value is less than 90.

#### Definition

**Blood Pressure:** CRS uses mean of last 3 Blood Pressures documented on non-ER visits during the Report Period. If 3 BPs are not available, uses mean of last 2 non-ER BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not BOTH meet the specified criteria, then the value is not included in the numerator.

If CRS is not able to calculate a mean BP, it will search for the most recent of any of the following CPT codes documented on non-ER visits during the Report Period. The systolic and diastolic values do NOT have to be recorded on the same day. If there are multiple values on the same day, the CPT indicating the lowest value will be used.

Systolic: 3074F, 3075F, 3076F (old code), or 3077F WITH Diastolic: 3078F, 3079F, or 3080F.

The following combinations represent BP <140/90 and will be included in the numerator:

- 1) CPT 3074F AND 3078F,
- 2) 3074F AND 3079F,
- 3) 3075F AND 3078F,
- 4) 3075F AND 3079F,
- 5) CPT 3076F AND 3078F,
- 6) CPT 3076F AND 3079F.

All other combinations will NOT be included in the numerator.

**Patient List**

Diabetic patients with mean BP, if any.

### 2.1.3 Diabetes: LDL Control

**Changes from Version 8.0 Patch 3 noted below.**

**Owner/Contact**

Diabetes Program/Dr. Marie Russell

**Denominator**

**QoC:** Active Diabetic patients, defined as all Active Clinical patients diagnosed with diabetes prior to the Report period, AND at least 2 visits during the Report period, AND 2 DM-related visits ever.

**Numerator**

**QoC:** Patients with LDL result less than (<) 100.

**Definition**

**LDL Screening:** LDL Screening: Searches for most recent LDL test during the Report Period. *If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.* LDL defined as: CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, or 3050F; LOINC taxonomy; or site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX.

The following will be included in the numerator:

- 1) Lab tests with a result of <100,
- 2) CPT 3048F.

Not included in the numerator are:

- 1) LDL tests with no result or result =>100,
- 2) CPT 80061, 83700, 83701, 83704, 83715, 83716, 83721, 3049F, 3050F.

**Patient List**

Diabetic patients with most recent LDL test, if any.

## 2.1.4 Adult Immunizations: Influenza

Changes from Version 8.0 Patch 3 noted below.

### Owner/Contact

Epidemiology Program/ Amy Groom, MPH

### Denominators

- 1) **QoC:** Active Clinical patients ages 50-64.
- 2) **QoC:** *Active Clinical patients ages 65 and older*

### Numerators

- 1) **QoC:** Patients with influenza vaccine or refusal documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.
  - A) Patients with documented refusal.
  - B) Patients with a contraindication or a documented NMI (not medically indicated) refusal.

### Definition

- 1) **Age:** Age of the patient is calculated at the beginning of the Report Period.
- 2) **Influenza Vaccine:** Any of the following documented during the Report Period unless otherwise noted:
  - A) **Influenza immunization**, defined as:
    - 1) Immunization (CVX) codes: 88-Influenza Virus Vaccine, NOS; 15 Inf Virus Vac SV; 16 Inf Virus Vac WV; 111 Inf Virus Vac Intranasal;
    - 2) POV: V04.8 (old code), V04.81, or V06.6; CPT: 90655-90662, 90724 (old code), G0008, G8108; ICD Procedure code: 99.52;
  - B) **Contraindication** documented at any time before the end of the Report Period, defined as:
    - 1) Contraindication in the Immunization Package of “Egg Allergy” or “Anaphylaxis” or
    - 2) PCC NMI Refusal;
  - C) **Refusal** of immunization codes 88, 111, 15, or 16, as documented in PCC Refusal File (i.e., REF) or in the Immunization Package as contraindication of “Patient Refusal.”

### Patient List

List of patients 50 *years and older (changed from age range 50-64 yrs)* with influenza immunization, contraindication, or refusal, if any.

## 2.1.5 Adult Immunizations: Pneumovax

**Topic added from the National GPRA Report included in CRS Version 8.0 Patch 3. Changes from CRS Version 8.0 Patch 3 are noted below.**

### Owner/Contact

Epidemiology Program/Amy Groom, MPH

### Denominator

**QoC:** Active Clinical patients ages 65 and older

### Numerators

- 1) **QoC:** Patients with influenza vaccine or refusal documented during the Report Period or with a contraindication documented at any time before the end of the Report Period.
  - A) Patients with documented refusal.
  - B) Patients with a contraindication or a documented NMI (not medically indicated) refusal.

### Definition

- 1) **Age:** Age of the patient is calculated at the beginning of the Report period.
- 2) **Pneumovax** defined as any of the following documented anytime before the end of the Report Period unless otherwise noted.
  - A) **Pneumococcal Immunization** defined as:
    - 1) (CVX) codes: 33 Pneumo Polysaccharide; 100 Pneumo Conjugate; 109 Pneumo NOS;
    - 2) POV: V06.6 or V03.82;
    - 3) V Procedure: 99.55;
    - 4) CPT: 90669, 90732, G0009, G8115
  - B) **Contraindication**, defined as:
    - 1) Contraindication in the Immunization Package of "Anaphylaxis" or
    - 2) PCC NMI Refusal.
  - C) **Refusal** during the Report Period:
    - 1) Immunization codes 33, 100, or 109, as documented in PCC Refusal File (i.e., REF) or
    - 2) Immunization Package as contraindication of "Patient Refusal".

### Patient List

List of patients 65 years or older with pneumovax, contraindication, or refusal, if any.

## 2.1.6 Use of Appropriate Medications for People with Asthma

Changes from Version 8.0 Patch 3 noted below.

### Owner/Contact

Drs. Charles (Ty) Reidhead and Charles North

### Denominators

- 1) **QoC:** Active Clinical patients ages 5-56 with persistent asthma within the year prior to the beginning of the Report Period and during the Report Period, without a documented history of emphysema or chronic obstructive pulmonary disease (COPD).
  - A) Active Clinical patients ages 5-9.
  - B) Active Clinical patients ages 10-17.
  - C) Active Clinical patients ages 18-56

### Numerator

**QoC:** Patients who had at least one dispensed prescription for (*DELETED: primary*) *preferred* asthma therapy medication during the Report Period.

### Denominator Exclusions

Patients diagnosed with emphysema or COPD at any time on or before the end of the Report Period are excluded from the denominator.

### Definition

- 1) **Age:** Age of the patient is calculated at the beginning of the Report Period.
- 2) **Emphysema:** Any visit with POV codes: 492.\*, 506.4, 518.1, 518.2.
- 3) **Chronic Obstructive Pulmonary Disease (COPD):** Any visit with POV codes: 491.20, 491.21, 491.22, 493.2\*, 496, 506.4.
- 4) **Persistent Asthma:**
  - A) Meeting any of the following four criteria below within the year prior to the beginning of the Report period AND during the Report period:
    - 1) At least one visit to Clinic Code 30 (Emergency Medicine) with primary diagnosis 493\* (asthma).
    - 2) At least one acute inpatient discharge with primary diagnosis 493.\*. Acute inpatient discharge defined as Service Category of H.
    - 3) At least four outpatient visits, defined as Service Categories A, S, or O, with primary or secondary diagnosis of 493.\* AND at least two asthma medication dispensing events (see definition below).

- 4) At least 4 asthma medication dispensing events (see definition below). If the sole medication was leukotriene modifiers, then **MUST** also (**DELETED meet criteria in 1-3 above or**) have at least one visit with POV 493.\* in the same year as the leukotriene modifier (i.e., during the Report period or within the year prior to the beginning of the Report period.) OR

**B) Meeting the following criteria below: (**DELETED: categorized in the Asthma Register System (ARS)**)**

- 1) **Active entry in PCC Problem List for 493.\*** with Severity of 2, 3 or 4 at ANY time before the end of the Report Period, or
- 2) **Most recent visit-related asthma entry (i.e., V Asthma) with Severity of 2, 3, or 4 documented ANY time before the end of the Report Period.**

**Dispensing Event:** One prescription of an amount lasting 30 days or less. For RXs longer than 30 days, divide the days' supply by 30 and round down to convert. For example, a 100-day RX is equal to three dispensing events (100/30 = 3.33, rounded down to 3). Also, two different RXs dispensed on the same day are counted as two different dispensing events. Inhalers should also be counted as one dispensing event.

**Note:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date.  
Example: Rx Date = 11/15/2003, Discontinued Date = 11/19/2003, Recalculated # Days Prescribed = 4.

**Asthma medication codes for denominator** Asthma medication codes for denominator defined with medication taxonomies: BGP HEDIS ASTHMA MEDS, BGP HEDIS ASTHMA LEUK MEDS, BGP HEDIS ASTHMA INHALED MEDS. (Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), **Antibody Inhibitor (Omalizumab)**, Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Belclomethasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Leukotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Long-Acting, Inhaled Beta-2 Agonists (Aformoterol, Formoterol, Salmeterol), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxitriphylline, Theophylline), Short-Acting, Inhaled Beta-2 Agonists (Albuterol, Levalbuterol, **Metaproterenol**, Pirbuterol).

- 5) (**DELETED: Primary Preferred Asthma Therapy:** To be included in the numerator, patient must have a non-discontinued prescription for preferred asthma therapy (see list of medications below) during the Report Period.

***(DELETED: Primary) Preferred asthma therapy medication codes for numerator*** defined with medication taxonomy: BGP HEDIS PRIMARY ASTHMA MEDS Medications are: Antiasthmatic Combinations (Dyphylline-Guaifenesin, Guaifenesin-Theophylline, Potassium Iodide-Theophylline), ***Antibody Inhibitor (Omalizumab)***, Inhaled Steroid Combinations (Budesonide-Formoterol, Fluticasone-Salmeterol), Inhaled Corticosteroids (Belclomethasone, Budesonide, Flunisolide, Fluticasone CFC Free, Mometasone, Triamcinolone), Lekotriene Modifiers (Montelukast, Zafirlukast, Zileuton), Mast Cell Stabilizers (Cromolyn, Nedocromil), Methylxanthines (Aminophylline, Dyphylline, Oxtriphylline, Theophylline).

**Patient List**

Asthmatic patients with primary asthma therapy medications, if any.

## 2.1.7 Community-Acquired Pneumonia (CAP) Assessment of Oxygen Saturation (Changed from Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia)

Changes from Version 8.0 Patch 3 noted below.

### Owner/Contact

Dr. Charles (Ty) Reidhead

### Denominator

**QoC:** Number of visits for User Population patients ages 18 and older diagnosed with community-acquired bacterial pneumonia at an outpatient visit during the Report Period.

### Numerators

- 1) **QoC:** Number of visits where patients had oxygen saturation documented and reviewed.
- 2) Number of visits where patients refused oxygen saturation assessment.
- 3) Number of visits where patients did not have their oxygen saturation documented and reviewed.

### Definition

- 1) **Age:** Age of the patient is calculated at the beginning of the Report Period.
- 2) **Community-acquired Bacterial Pneumonia:** Non-CHS outpatient visit (defined as (visit) Type not equal to C and Service Category of A (Ambulatory), S (Day Surgery), or O (Observation)) with POV 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39, 482.40, 482.41, 482.42, 482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9, 483.0, 483.1, 483.8, 485, 486, or 487.0.

If a patient has more than one visit for community-acquired bacterial pneumonia during the Report Period, each visit will be counted as long as it has been more than 45 days since the date of the prior visit. For example, a patient was diagnosed on January 1, 2008 and 35 days later he was diagnosed again with pneumonia. That second diagnosis does not count as a separate visit. However, if the patient were diagnosed again on February 16, 2008 (46 days after onset), that diagnosis counts as a separate visit. Because RPMS does not store the date of onset, visit date will be used as a surrogate for onset date.

- 3) **Oxygen Saturation Assessment:** Having any of the following arterial blood gas (ABG) or pulse oximetry tests performed at the visit:
  - A) V Measurement O2 Saturation;
  - B) V CPT 94760-94762, 82803, 82805, 82810, or 3028F, where 3028F has no modifier of 1P, 2P, 3P, or 8P;`s
  - C) lab test ABG;

- D) site-populated lab taxonomy BGP CMS ABG TESTS; or
  - E) LOINC taxonomy.
- 4) **Refusal of Oxygen Saturation Assessment:** Patients whose oxygen saturation was not assessed due to a patient refusal of assessment on visit date. Refusal is defined as refusal of any of the tests listed above.
  - 5) **No Assessment:** Patients whose oxygen saturation was not assessed or refused.

**Patient List**

Patients with community-acquired bacterial pneumonia, with oxygen saturation assessment or documented reason for no assessment, if any.

## 2.1.8 Persistence of Beta-Blocker Treatment After a Heart Attack

Topic added from the HEDIS Report included in CRS Version 8.0 Patch 3. Changes from CRS Version 8.0 Patch 3 are noted below.

### Owner/Contact

Dr. Eric Brody/Mary Wachacha & Chris Lamer, PharmD

### Denominators

- 1) **QoC:** Active Clinical patients 18 and older diagnosed with an AMI six months prior to the Report period through the first six months of the Report period and do not have a contraindication/previous adverse reaction to beta-blocker therapy. Broken down by gender.
  - A) Male Active Clinical patients 18 and older diagnosed with an AMI six months prior to the Report period through the first six months of the Report period and do not have a contraindication/previous adverse reaction to beta-blocker therapy.
  - B) Female Active Clinical patients 18 and older diagnosed with an AMI six months prior to the Report period through the first six months of the Report period and do not have a contraindication/previous adverse reaction to beta-blocker therapy.

### Numerator

**QoC:** Patients with a 135-day course of treatment with beta-blockers following first discharge date or visit date, including previous active prescriptions.

### Definition

- 1) **Denominator Exclusions are as follows:**
  - A) If inpatient visit, patients with Discharge Type of Irregular (AMA), Transferred, or contains "Death".
  - B) **Patients with contraindications to beta-blockers**, defined as occurring anytime through discharge date:
    - 1) Asthma - 2 diagnoses (POV) of 493\* on different visit dates;
    - 2) Hypotension - 1 diagnosis of 458\*;
    - 3) Heart block >1 degree - 1 diagnosis of 426.0, 426.12, 426.13, 426.2, 426.3, 426.4, 426.51, 426.52, 426.53, 426.54, or 426.7;
    - 4) Sinus bradycardia - 1 diagnosis of 427.81; or
    - 5) COPD - 2 diagnoses on different visit dates of 491.2\*, 496, or 506.4, or a combination of any of these diagnoses, such as one visit with 491.20 and one with 496.

- C) **Documented beta blocker allergy/ADR**, defined as occurring anytime through discharge/visit date: A) POV 995.0-995.3 AND E942.0; B) “beta block\*” entry in ART (Patient Allergies File); or C) “beta block\*”, “bblock\*” or “b block\*” contained within Problem List or in Provider Narrative field for any POV 995.0-995.3 or V14.8.
- 2) **Age** is calculated at the beginning of the Report period
  - 3) **Acute Myocardial Infarction (AMI)** defined as POV 410.\*0 or 410.\*1. AMI diagnosis may be made at an inpatient or outpatient visit but must occur between six months prior to beginning of Report period through first six months of the Report period. Inpatient visit defined as Service Category of H (Hospitalization). If patient has more than one episode of AMI during the timeframe, CRS will include only the first hospital discharge or ambulatory visit.
  - 4) **Numerator Logic:** To be included in the numerator, patients must have a beta-blocker days' supply  $\geq 135$  days in the 180 days following discharge date for inpatient visits or visit date for ambulatory visits. Prior active beta-blocker prescriptions can be included if the treatment days fall within the 180 days following discharge/visit date. Prior active prescription defined as most recent beta-blocker prescription (see codes below) prior to admission/visit date with the number of days supply equal to or greater than the discharge/visit date minus the prescription date.

**NOTE:** If the medication was started and then discontinued, CRS will recalculate the # Days Prescribed by subtracting the prescription date (i.e., visit date) from the V Medication Discontinued Date.  
 Example: Rx Date = 11/15/2003, Discontinued Date = 11/19/2003,  
 Recalculated # Days Prescribed = 4

Example of patient included in the numerator who has prior active prescription:

- Admission Date: 2/1/2004, Discharge Date: 2/15/2004
- Must have 135 days prescribed by 8/13/2004 (Discharge Date+180)
- Prior Beta-Blocker Rx Date: 1/15/2004
- # Days Prescribed: 60 (treats patient through 3/15/2004)
- Discharge Date minus Rx Date:  $2/15/2004 - 1/15/2004 = 31$ , 60 is  $\geq 31$ , prescription is considered Prior Active Rx
- 3/15/2004 is between 2/15 and 8/13/2004, thus remainder of Prior Active Rx can be counted toward 180-day treatment period
- # Remaining Days Prescribed from Prior Active Rx:  $(60 - (\text{Discharge Date} - \text{Prior Rx Date})) = 60 - (2/15/2004 - 1/15/2004) = 60 - 31 = 29$
- Rx #2: 4/1/2004, # Days Prescribed: 90

- Rx #3: 7/10/2004, #Days Prescribed: 90
  - Total Days Supply Prescribed between 2/15 and 8/13/2004: 29 + 90 + 90 = 209
- 5) **Beta-blocker medication codes** defined with medication taxonomy BGP HEDIS BETA BLOCKER MEDS. (*Medications are: Noncardioselective Beta Blockers: Carteolol, Carvedilol, Labetalol, Nadolol, Penbutolol, Pindolol, Propranolol, Timolol, Sotalol; Cardioselective Beta Blockers: Acebutolol, Atenolol, Betaxolol, Bisoprolol, Metoprolol, Nebivolol; and Antihypertensive Combinations: Atenolol-chlorthalidone, Bendroflumethiazide-nadolol, Bisoprolol-hydrochlorothiazide, Hydrochlorothiazide-metoprolol, Hydrochlorothiazide-propranolol, and Hydrochlorothiazide-timolol.*)  
(Updated list of medications).

**Patient List**

List of patients with AMI, with all beta-blocker prescriptions during the 180-day timeframe, if any.

## 2.1.9 Controlling High Blood Pressure

**Topic added from the HEDIS Report included in CRS Version 8.0 Patch 3. Changes from CRS Version 8.0 Patch 3 are noted below.**

### Owner/Contact

Dr. Eric Brody/ Mary Wachacha & Chris Lamer, PharmD

### Denominator

**QoC:** All Active Clinical patients ages 18 through 85 diagnosed with hypertension and no documented history of ESRD

### Numerators

- 1) Number of patients with Blood Pressure value documented during the Report period
- 2) **QoC:** Patients with adequately controlled blood pressure, defined as <140/90, i.e., the mean systolic value is less than 140 AND the mean diastolic value is less than 90.

### Definitions

- 1) **Age** of the patient is calculated at beginning of the Report period.
- 2) **End Stage Renal Disease (ESRD)** diagnosis/treatment defined as any of the following ever:
  - A) V CPT 36145, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831-36833, 50300, 50320, 50340, 50360, 50365, 50370, 50380, **90951-90970 or old codes** 90918-90925, 90935, 90937, 90939 (old code), 90940, 90945, 90947, 90989, 90993, 90997, 90999, 99512, G0257, G0308-G0327, **G0392, G0393**, or S9339;
  - B) V POV 585.5, 585.6, V42.0, V45.1 (*old code*), **V45.11, V45.12**, or V56.\*;
  - C) V Procedure 38.95, 39.27, 39.42, 39.43, 39.53, 39.93-39.95, 54.98, or 55.6\*.
- 3) **Hypertension** is defined as diagnosis (POV or problem list) 401.\* prior to the Report period, and at least one hypertension POV during the Report period.
- 4) **BP Values** CRS uses mean of last 3 Blood Pressures documented on non-ER visits during the Report Period. If 3 BPs are not available, uses mean of last 2 non-ER BPs. If a visit contains more than 1 BP, the lowest BP will be used, defined as having the lowest systolic value. The mean Systolic value is calculated by adding the last 3 (or 2) systolic values and dividing by 3 (or 2). The mean Diastolic value is calculated by adding the diastolic values from the last 3 (or 2) blood pressures and dividing by 3 (or 2). If the systolic and diastolic values do not BOTH meet the current category, then the value that is least controlled determines the category. For the BP documented numerator only, if CRS is not able to calculate a mean BP, it will search for CPT 3074F-3080F documented on non-ER visit during the Report Period.

**Patient List**

List of patients with hypertension and BP value, if any.

## 2.1.10 Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation at Discharge

Changes from Version 8.0 Patch 3 noted below.

### Owner/Contact

Dr. Eric Brody

### Denominator

**QoC:** Number of visits for User Population patients ages 18 and older who were discharged with ischemic stroke or transient ischemic attack (TIA) with documented permanent, persistent, or paroxysmal atrial fibrillation.

### Numerators

- 1) **QoC:** Number of visits where patients received a prescription for anticoagulant at discharge.
- 2) Number of visits where patients refused anticoagulant therapy.
- 3) Number of visits where patients did not receive anticoagulation therapy.

### Definition

- 1) **Age:** Age is calculated as of the beginning of the report period.
- 2) **Ischemic Stroke or Transient Ischemic Attack (TIA) with Atrial Fibrillation:** Non-CHS inpatient visit (Type not equal to "C" and Service Category = "H") and POV of any of the following: (433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01, 434.11, 434.91, 435.0, 435.1, 435.2, 435.3, 435.8, or 435.9) AND POV 427.31 (atrial fibrillation).
- 3) **Anticoagulant Therapy:** Patient must meet one of the conditions below to be counted as receiving anticoagulant therapy.
  - A) Active prescription for Warfarin, aspirin, or other anti-platelet as of discharge date. "Active" prescription defined as: Rx Days Supply  $\geq$  (Discharge Date - Prescription Date), where the prescription has not been discontinued as of the discharge date.
  - B) Prescription for Warfarin, aspirin, or other anti-platelet on discharge date.
- 4) **Warfarin Medication:** Any medication in site-populated BGP CMS WARFARIN MEDS taxonomy.
- 5) **Aspirin Medication:** Any medication in site-populated DM AUDIT ASPIRIN DRUGS taxonomy (*DELETED: CPT G8006*).
- 6) **Other Anti-Platelet/Anticoagulant Medication:** Any medication in the site-populated BGP ANTI-PLATELET DRUGS taxonomy, any medication with VA Drug Class BL700, (*DELETED: CPT 4073F or 4075F, where the CPT code does not have a modifier of 1P, 2P, or 8P*).
- 7) **Refusal of Anticoagulant Therapy:** Refusal of any of the following documented on discharge date:

- A) Any medication in site-populated taxonomies BGP CMS WARFARIN MEDS, DM AUDIT ASPIRIN DRUGS, or BGP ANTI-PLATELET DRUGS; or
  - B) Any medication with VA Drug Class BL700; (*DELETED: CPT G8006, 4073F, or 4075F*).
- 8) **No Anticoagulant Therapy:** Patients who did not have an active prescription for anticoagulant therapy at time of discharge and did not receive or refuse anticoagulant therapy at discharge.

**Patient List**

Patients with stroke/TIA and atrial fibrillation with anticoagulant therapy, if any.

## 2.1.11 Cholesterol Management for Patients with Cardiovascular Conditions

**Topic added from the HEDIS Report included in CRS Version 8.0 Patch 3. Changes from CRS Version 8.0 Patch 3 are noted below.**

### Owner/Contact

Dr. Eric Brody

### Denominator

**QoC:** Active Clinical patients ages 18 to 75 who, during the first 10 months of the year prior to the beginning of the Report Period, were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) OR who were diagnosed with ischemic vascular disease (IVD) during the Report Period and the year prior to the Report Period.

### Numerators

- 1) Patients with LDL completed during the Report Period, regardless of result.
- 2) **QoC:** Patients with LDL <100 during the Report Period.

### Definition

- 1) **Age** of the patient is calculated at the beginning of the Report period.
- 2) **AMI** defined as POV 410.\*0 or 410.\*1.
- 3) **PTCA** defined as
  - A) V Procedure 00.66, 36.01 (old code), 36.02 (old code), 36.05, (old code), 36.06-36.07, or 36.09 or
  - B) CPT 33140, 92980, (~~DELETED: 92981~~), 92982, (~~DELETED: 92984~~), 92995, (~~DELETED: 92996~~).
- 4) **CABG** defined as:
  - A) V Procedure 36.1\*, 36.2 or
  - B) CPT 33510-33514, 33516-33519, 33521-33523, 33533-33536, (~~DELETED: 35600, 33572~~) S2205-S2209.
- 5) **IVD** defined as: 411.\*, 413.\*, 414.0\*, **414.2**, 414.8, 414.9, 429.2, 433.\*-434.\*, 440.1, 440.2\*, **440.4**, 444.\*, or 445.\*.
- 6) **LDL Screening:** (*Changed from Searches for most recent LDL test with a result during the Report Period. If none found, CRS searches for the most recent LDL test without a result*) Searches for an LDL test during the Report Period. LDL defined as: CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F; LOINC taxonomy; site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX.

LDL <100: Searches for most recent LDL test during the Report Period. *If more than one LDL test is found on the same day and/or the same visit and one test has a result and the other does not, the test with the result will be used.*

LDL defined as: CPT 80061, 83700, 83701, 83704, 83715 (old code), 83716 (old code), 83721, 3048F, 3049F, 3050F; LOINC taxonomy; site-populated taxonomy DM AUDIT LDL CHOLESTEROL TAX. **The following will be included in the numerator:**

- A) *Lab tests with a result of <100,*
- B) *CPT 3048F.*

**Not included in the numerator are:**

- A) *LDL tests with no result or result =>100,*
- B) *CPT 80061, 83700, 83701, 83704, 83715, 83716, 83721, 3049F, 3050F.*

#### **Patient List**

List of patients with AMI, CABG, PTCA, or IVD w/LDL value, if any.

## 3.0 Contact Information

If you have any questions or comments regarding this distribution, please contact the OIT Help Desk (IHS).

**Phone:** (505) 248-4371 or (888) 830-7280 (toll free)

**Fax:** (505) 248-4363

**Web:** <http://www.ihs.gov/GeneralWeb/HelpCenter/Helpdesk/index.cfm>

**Email:** [support@ihs.gov](mailto:support@ihs.gov)